Aadi Bioscience : Corporate Overview

Corporate Overview

December 2021

NASDAQ: AADI

www.aadibio.com

Aadi Bioscience Inc., Pacific Palisades, CA 90272, USA1

Cautionary Note Regarding Forward-Looking Statements

Certain statements contained in this presentation regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation

Act of 1995, known as the PSLRA. These include statements regarding management's intention, plans, beliefs, expectations or forecasts for the future, and, therefore, you are cautioned not to place undue reliance on them. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Aadi Bioscience, Inc. ("Aadi") undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law. We use words such as "anticipates," "believes," "plans," "expects," "projects," "intends," "may," "will," "should," "could," "estimates," "predicts," "potential," "continue," "guidance," and similar expressions to identify

these forward-looking statements that are intended to be covered by the safe-harbor provisions of the PSLRA.

Such forward-looking statements are based on our expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including, but not limited to, Aadi's plans to develop and commercialize its product candidates, including FYARRO™ (nab-sirolimus,ABI-009); Aadi's commercialization, marketing and manufacturing capabilities and strategy; the clinical utility, potential benefits and market acceptance of FYARRO and any other of Aadi's product candidates; risks related to the sufficiency Aadi's cash balance to fund

operations; the timing of initiation of Aadi's planned clinical trials; the timing of the availability of data from Aadi's clinical trials; Aadi's plans to research, develop and commercialize its current and future product candidates; Aadi's ability to successfully enter into collaborations, and to fulfill its obligations under any such collaboration agreements; Aadi's ability to identify additional products or product candidates with significant commercial potential; developments and projections relating to Aadi's competitors and our its industry; the impact of government laws and regulations; Aadi's ability to protect its intellectual property position; the impact of the COVID-19 outbreak on Aadi's operations, the biotechnology industry and the economy generally and Aadi's estimates regarding future revenue, expenses, capital requirements and need for additional financing.

These risks are described in detail under the caption "Risk Factors" in Aadi's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, filed with the Securities and Exchange Commission (the "SEC") on November 10, 2021, and other documents filed from time to time with the SEC. Forward-looking statements included in this presentation are based on information available to Aadi as of the date of this presentation. Aadi undertakes any obligation to such forward-looking statements to reflect events or circumstances after the date of this presentation.

2

FYARRO Granted Full Approval Following Priority Review by the FDA

FDA Approval Nov 22, 2021

First and only therapy approved to treat locally advanced unresectable or metastatic malignant PEComa

Albumin-boundmTOR inhibitor leveraging nab-technology to deliver a favorable clinical profile in an area of high unmet medical need

Efficacy defined by ORR and DOR in the prescribing information

Adverse event profile that is predictable and manageable

3

Aadi Bioscience is a Commercial-Stage, Precision Oncology Company Re-engineering mTOR Inhibition

• Focused on the commercialization of FYARROTM (sirolimus protein-bound particles for injectable suspension [albumin-bound],nab-sirolimus), an albumin-bound mTOR inhibitor developed using the validated nanoparticle albumin-based (nab) platform proven with ABRAXANE®
• FYARRO™ now FDA approved as the only product indicated for locally advanced unresectable or metastatic malignant PEComa; commercial preparations underway ahead of Q1 2022 launch

NASDAQ: AADI

• New registrational study to be initiated pursuing a significant potential opportunity in tumor- agnostic TSC1 or TSC2 inactivating alterations in solid tumors - recent data (ASCO 2021) suggests encouraging activity of ABI-009
• Cash runway into 2024 to support commercialization and future clinical development of FYARRO™

4

Leadership: We are Building a World-Class Team with Deep Expertise in Oncology Commercialization and Development

Neil Desai, PhD	Brendan Delaney, MBA	Scott Giacobello, CPA	Loretta Itri, MD
Founder, CEO	Chief Operating Officer	Chief Financial Officer	Chief Medical Officer
and President
• Former Sr VP, Global	• Previously CCO at	• Previously CFO GW	• Previously CMO at
R&D at Abraxis	Constellation Pharma	Pharmaceuticals	Immunomedics
Bioscience	(acquired by MorphSys)	• Former CFO Chase	• Former EVP Global
• Previously Vice	• Former CCO at
Pharmaceutical Corp.;	Health Sciences &
President, Strategic	Immunomedics	EVP&CFO VIZI Health	Regulatory Affairs, The
Platforms, Celgene;	(acquired by Gilead); VP	Solutions; VP Finance-	Medicines Company;
prior positions of	of US Hematology	Global R&D Allergan as	President,
increasing seniority at	/Oncology at Celgene	well as VP Corporate	Pharmaceutical
American BioScience,	• 25+ years commercial	Finance and VP Finance	Development, CMO
Inc.	- Audit and Compliance	Genta, Inc.; SVP, WW
• Inventor of the nab	experience including	• 13+ years	Clinical Affairs at
prior roles at Novartis	Johnson & Johnson,
technology (Abraxane	Oncology and	pharmaceutical finance	Ortho Biotech
and ABI-009)	Genentech	experience	• 40+ years drug
• 25+ years in R&D
		development
			experience

Mitchall Clark,	Lynn Samuel	Andrew Kwon,
BPharm, MRPharmS	VP Manufacturing and	PhD, MBA
SVP Regulatory Affairs and	Supply Chain	VP BD & Corporate
Quality Assurance		Strategy
• Previously Chief	• Previously SVP Global	• Previously Principal,
Regulatory / Quality	Supply Chain, Nant	Acsel Health; Director,
Officer, Atara	BioScience	Syneos Health
Biotherapeutics	• Former SVP Global	Consulting
• Former SVP Regulatory	• Former Research
Quality Assurance,
Affairs at Abraxis	ImmunityBio; VP	Scientist at Memorial
Bioscience	Manuf. Operations,	Sloan Kettering Cancer
• Worldwide regulatory	NantPharma;	Center
• Sr. Dir., Nanotechnology	• 14+ years biotech
experience with
Abraxane; 25+ years in	Program, Abraxis	industry experience
regulatory affairs	BioScience; led	focused on Business
	Abraxane manufacturing	Development and
	in >37 countries	Commercial Strategy in
	• 40+ years in	oncology
	pharmaceutical
	operations

5